echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The United States approved Roche's new all-tumor liquid biopsy testing platform.

    The United States approved Roche's new all-tumor liquid biopsy testing platform.

    • Last Update: 2020-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    U.S. regulators have approved Roche's new Full Tumor Liquid Biopsy Test Platform (FoundationOne Liquid CDx) for patients with solid tumors, which will provide an alternative for patients who are unable to perform an tissue biopsy.
    FoundationOne Liquid CDx is a Genomic Analysis (CGP) test that analyzes more than 300 cancer-related genes and multiple genomic characteristics to identify genetic mutations in tumors and optimize patient care.
    One Liquid CDx was able to analyze cellless DNA circulating in a patient's blood sample and use large-scale parallel sequencing to detect four major genomic changes.
    regulator also approved the test to identify patients who may benefit from certain prostate and lung cancer treatments, including Rucaparib and three first-line tyrosine kinase (TKI) inhibitors.
    cancer patients are unable to perform tissue biopsies," said Levi Garraway, chief medical officer and executive vice president of Roche.
    One Liquid CDx may offer minimally invascopic treatment options for patients who might not otherwise benefit from comprehensive genomic analysis.
    the convenience of testing blood samples can also make treatment decisions faster, so that patients can rest assured that time is wasted and time is buyable for efficient treatment."
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.